Jordan Milner

Jordan Milner, MD

Pediatric BMT And Cellular Therapy Program Director

Department: MD-PEDS-HEMATOLOGY
Business Phone: (352) 273-9120
Business Email: jordan.milner@ufl.edu

About Jordan Milner

Hello, my name is Jordan Milner, MD, and I am a clinical assistant professor in the division of pediatric hematology oncology at the University of Florida College of Medicine Department of Pediatrics. I became interested in medicine because of the wonderful relationships that are built between physicians and patients and because the field of medicine is always evolving and advancing. I chose pediatric bone marrow transplant (BMT) because I care about patients and helping them face complex underlying diseases.

In medical school, I was a member of the Global Scholar Program at St. George’s University School of Medicine for medical students who exhibit academic excellence. I completed my pediatric residency and chief year at Memorial University Medical Center in Savannah, GA, and went on to complete a fellowship in pediatric hematology/oncology at Maria Fareri Children’s Hospital at Westchester Medical Center in Valhalla, NY.

I have a strong passion for stem cell transplantation and cellular therapies and have dedicated my research to stem cell graft manipulation and virus specific cytotoxic T-lymphocytes. At the Pediatric Blood & Marrow Transplantation and Cell Therapy Program, we are currently working to bring alpha/beta T cell and B cell depletion for allogeneic stem cell transplants to UF and look forward to opening several trials utilizing this graft manipulation.

I look forward to continuing to serve as an advocate, helping to improve the curative treatment options for sickle cell disease and bring them to the University of Florida.

I am so happy to be a part of a team of innovative experts at the University of Florida. I am a native Floridian and I love to be outside with my family, especially by the water. I enjoy dancing and travelling abroad.

As a pediatric BMT and cellular therapy physician, I often times become a part of the patient’s family and enjoy advocating for what’s medically best for them. I look forward to providing outstanding and compassionate care to patients and their families here at UF Health.

Board Certifications

  • Pediatric Hematology-Oncology
    American Board of Pediatrics
  • Pediatrics
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML) – children
  • Aplastic anemia
  • Sickle cell disease

Research Profile

Dr. Milner’s research focus is graft manipulation. The utilization of graft manipulation permits decreased morbidities and improved quality of life in stem cell transplant recipients.

Open Researcher and Contributor ID (ORCID)

0000-0001-5768-7745

Areas of Interest
  • Allogeneic Hematopoietic Cell Transplantation
  • Bone marrow transplantation
  • Cellular Immunotherapy
  • Hematology
  • Hematology and Oncology
  • Hematopoietic Stem Cell Transplantation
  • Malignant Hematologic Disorders
  • Prevention of relapse following bone marrow transplantation
  • Sickle Cell Anemia

Publications

2024
The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.
Pediatric transplantation. 28(4) [DOI] 10.1111/petr.14784. [PMID] 38766976.
2023
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
Blood. 142(24):2105-2118 [DOI] 10.1182/blood.2022019586. [PMID] 37562003.
2022
Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients
Cureus. 14(9) [DOI] 10.7759/cureus.29195.
2022
Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant
Bone Marrow Transplant. 57(4):586-592 [DOI] 10.1038/s41409-022-01584-y.
2021
Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation
Bone Marrow Transplant. 56(9):2221-2230 [DOI] 10.1038/s41409-021-01298-7.
2018
B-precursor Acute Lymphoblastic Leukemia Complicating 18q Deletion Syndrome
Pediatric Blood Cancer. 65(12) [DOI] 10.1002/pbc.27436.
2009
Impact of physicians’ discomfort and patient prognosis on discussion of fertility preservation with young cancer patients
Patient Education and Counseling. 77(3):338-343

Grants

Jan 2024 ACTIVE
Clinical Outcomes of Pediatric MDS: A Retrospective Review by the North American Pediatric Aplastic Anemia Consortium (NAPAAC)
Role: Principal Investigator
Funding: CHILDRENS HOSPITAL COLORADO via SWIM ACROSS AMERICA
Jun 2023 ACTIVE
Utilization of Alpha/Beta T Cell and B Cell Depletion in Allogeneic Stem Cell Transplantation in Malignant Diseases
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
May 2023 ACTIVE
Safety & Efficacy of Prophylactic Defibrotide Admin in CAYA w/Sickle Cell Disease or Beta Thalassemia Following MAC & Haplo Stem Cell Transplant Utilizing CD34 Enrichment & T-Cell(CD3) Addback
Role: Principal Investigator
Funding: NEW YORK MEDICAL COLLEGE via JAZZ PHARMACEUTICALS
Dec 2022 ACTIVE
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT)
Role: Principal Investigator
Funding: NATL MARROW DONOR PROGRAM via NATL INST OF HLTH NHLBI
Apr 2022 ACTIVE
Engineered Donor Graft for Pediatric Hematopoietic Cell Transplant (HCT) Recipients with Hematologic Malignancies (HM)- Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC) First Prospective Multicenter Trial
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jul 2019 ACTIVE
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID receiving TCRaB+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatr
Role: Principal Investigator
Funding: CHILDRENS HOSP LOS ANGELES via NATL INST OF HLTH
Sep 2018 ACTIVE
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
Role: Principal Investigator
Funding: PEDIATRIC BLOOD AND MARROW TRANSPLANT CO

Education

Pediatric Hematology/Oncology/BMT Fellowship
2017-2020 · Maria Fareri Children's Hospital at Westchester Medical Center
Pediatric Residency
2014-2017 · Memorial Health University Medical Center
Medical Degree
2014 · St. George's University School of Medicine
Bachelor of Science
2009 · University of South Florida

Contact Details

Phones:
Business:
(352) 273-9120
Emails:
Addresses:
Business Street:
1600 SW ARCHER RD
GAINESVILLE FL 32610